Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01969123 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Phase 3 study, sponsored by FORUM Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 474
- Enrollment target
NCT01969123: Clinical Trial Phase 3 study, sponsored by FORUM Pharmaceuticals.
NCT01969123 is a Phase 3 study that was terminated before completion, run by FORUM Pharmaceuticals. The registered enrollment target is 474 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01969123, a Phase 3 study, was terminated before completion, sponsored by FORUM Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 474 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.
Interventions
- DRUG Placebo
- DRUG Drug: EVP-6124
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2013-10 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
Why NCT01969123 stopped before completion
NCT01969123 is an interventional study that assigns participants to a tested intervention. The registered 474 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01969123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01969123 about?
NCT01969123 is a clinical study titled "Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease". The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.
What is the current status of trial NCT01969123?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 474 participants. The study started on 2013-10. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01969123?
The interventions under investigation include: Placebo (DRUG), Drug: EVP-6124 (DRUG).
Who is sponsoring clinical trial NCT01969123?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01969123's enrollment target sits among peer trials
474 810th of 2000 higher than 1,190 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05624996 · 474 participants · Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- NCT06051695 · 474 participants · Phase 1
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- NCT06632977 · 474 participants · Phase 2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia